<DOC>
	<DOCNO>NCT00052065</DOCNO>
	<brief_summary>This dose-ranging , open-label , Phase 1-2a study TLK286 combination Doxil patient platinum refractory resistant ovarian cancer .</brief_summary>
	<brief_title>TLK286 Combination With Doxil Platinum Refractory Resistant Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Histologically cytologically confirm diagnosis epithelial cancer ovary , fallopian tube cancer primary peritoneal cancer Recurrent epithelial ovarian cancer persistent disease follow primary treatment At least one , four , prior platinumcontaining chemotherapy regimen At least one prior taxanecontaining regimen Exclusion Criteria A history prior malignancy except adequately treat carcinoma situ uterine cervix , basal cell squamous cell skin cancer , cancer patient diseasefree 2 year Known leptomeningeal metastasis carcinomatous meningitis Have receive prior Doxil liposomal doxorubicin Having receive whole pelvis radiation therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>